NICE Evidence Standard 2 reads as a UX requirement. It functions as a health equity standard — the line where DHT founders quietly decide which patients their product will work for.
NICE Evidence Standard 18 is the cost-effectiveness analysis most DHT founders treat as compliance — and the threshold that frames it has just moved for the first time in 27 years.
NICE ESF Standard 6 demands a clinical governance design, not a clinician disclaimer. Here’s what proportionate oversight actually looks like for founders.
32% of consumers now use AI chatbots for health information. For DHT founders, your real competitor isn’t the care pathway — it’s a free chatbot.
Why most DHT companies fail NICE Evidence Standard 15 — and how to design a real-world evidence programme that survives contact with the NHS.
NICE Evidence Standard 12 forces every DHT to answer one question: do you replace something, or add to it? The answer decides whether you ever scale.
NICE Evidence Standard 1 is the safety and quality foundation for any NHS-bound DHT. Why founders mis-read it, and what good looks like.
NICE Evidence Standard 4 requires DHTs to demonstrate bias mitigation across protected groups — not just document it. Here’s what it actually demands, where founders get it wrong, and how to build products that hold up under NHS scrutiny
Concept Development and Planning: Laying the Groundwork for Your Digital Health Tool Ever wondered how to turn your brilliant digital
What is Health Technology Assessment? Health Technology Assessment (HTA) is a process in which health technologies (including pharmaceuticals, procedures, medical
